Siemens Healthineers is exploring a possible divestment or spin-off of its Diagnostics division by 2030, as the company reshapes its portfolio and refocuses long-term growth.
CEO Bernd Montag said the business may no longer remain part of Healthineers if independence is deemed the better strategic path. No discussions with potential buyers have started yet.
📊 Key Details
- Timeline: Potential divestiture by 2030
- Growth Outlook (2027–2030):
- Imaging + Precision Therapy: 6–9% annual revenue growth
- Diagnostics: Improving toward mid-single-digit growth
- Tariffs Impact:
- €400M annual U.S. tariff burden expected to be fully offset by 2028 via pricing and productivity gains
- Parent Siemens’ Move:
- Siemens will reduce its stake in Healthineers from 67% → 37% or less, transferring shares to its shareholders
- Longer-term: stake may drop below 20%
🧭 Why It Matters
The Diagnostics business has faced margin pressure and operational challenges. A future spin-off could:
- Unlock targeted growth
- Improve operational focus
- Boost valuation transparency
- Allow Healthineers to double down on higher-growth segments like Imaging and Precision Therapy
Meanwhile, Siemens’ scaling back of its holding marks a continued shift toward its core strengths in mobility, automation, and smart infrastructure.